Patents by Inventor Celia Lafuente Blanco

Celia Lafuente Blanco has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • PYRROLIDINE COMPOUNDS
    Publication number: 20220169636
    Abstract: The present invention provides compounds of the Formula or a pharmaceutically acceptable salt thereof, and compounds processes for preparing the compounds and their salts, and a pharmaceutical composition.
    Type: Application
    Filed: February 15, 2022
    Publication date: June 2, 2022
    Inventors: Celia Lafuente BLANCO, Nuria Diaz BUEZO, Jose Antonio Martinez PEREZ, Gema Consuelo SANZ GIL, Julian Priego SOLER
  • Pyrrolidine compounds
    Patent number: 11286249
    Abstract: The present invention provides compounds of the Formula wherein L is selected from the group consisting of —CH2NHCH2—, —CH2NH—, —NH—, —S—, —S(O)—, —S(O)2—, —O—, —OCH2—, —OCH2CH2O—, —NHSO2NH—, or a pharmaceutically acceptable salt thereof; a compound of the formula: processes for preparing the compounds and their salts, a pharmaceutical composition, and methods of treating patients in need of such treatment.
    Type: Grant
    Filed: June 3, 2020
    Date of Patent: March 29, 2022
    Assignee: Eli Lilly and Company
    Inventors: Celia Lafuente Blanco, Nuria Diaz Buezo, Jose Antonio Martinez Perez, Gema Consuelo Sanz Gil, Julian Priego Soler
  • PYRROLIDINE COMPOUNDS
    Publication number: 20210253559
    Abstract: The present invention provides compounds of the Formula wherein L is selected from the group consisting of —CH2NHCH2—, —CH2NH—, —NH—, —S—, —S(O)—, —S(O)2—, —O—, —OCH2—, —OCH2CH2O—, —NHSO2NH—, or a pharmaceutically acceptable salt thereof; a compound of the formula: processes for preparing the compounds and their salts, a pharmaceutical composition, and methods of treating patients in need of such treatment.
    Type: Application
    Filed: June 3, 2020
    Publication date: August 19, 2021
    Inventors: Celia Lafuente BLANCO, Nuria Diaz BUEZO, Jose Antonio Martinez PEREZ, Gema Consuelo SANZ GIL, Julian Priego SOLER
  • DGAT2 inhibitors
    Patent number: 10053429
    Abstract: The present invention provides compounds of the Formula below: [Formula should be inserted here] Where A, X, R. and R2-R3 are as described herein; methods of treating patients for hypertriglyceridemia and cardiovascular disease including dyslipidemia and atherosclerosis, and processes for preparing the compounds.
    Type: Grant
    Filed: May 19, 2016
    Date of Patent: August 21, 2018
    Assignee: Eli Lilly and Company
    Inventors: Ana Maria Escribano, Maria Rosario Gonzalez, Celia Lafuente Blanco, Maria Dolores Martin-Ortega Finger, Michael R Wiley
  • NOVEL DGAT2 INHIBITORS
    Publication number: 20180162825
    Abstract: The present invention provides compounds of the Formula below: [Formula should be inserted here] Where A, X, R, and R2-R3 are as described herein; methods of treating patients for hypertriglyceridemia and cardiovascular disease including dyslipidemia and atherosclerosis, and processes for preparing the compounds.
    Type: Application
    Filed: May 19, 2016
    Publication date: June 14, 2018
    Applicant: Eli Lily and Company
    Inventors: Ana Maria Escribano, Maria Rosario Gonzalez, Celia Lafuente Blanco, Maria Dolores Martin-Ortega Finger, Michael R Wiley
  • SPIROPIPERIDINE COMPOUNDS AS ORL-1 RECEPTOR ANTAGONISTS
    Publication number: 20120214784
    Abstract: An ORL-1 receptor antagonist of the formula: its uses, and methods for its preparation are described. ORL-1 antagonists are deemed to be useful in the treatment of depression and/or the treatment of overweight, obesity, and/or weight maintenance post treatment for overweight or obesity. Certain compounds have also demonstrated through animal models that the compounds of the present invention are useful for the treatment of migraines.
    Type: Application
    Filed: November 12, 2010
    Publication date: August 23, 2012
    Applicant: ELI LILLY AND COMPANY
    Inventors: Ana Belen Benito Collado, Nuria Diaz Buezo, Alma Maria Jimenez-Aguado, Celia Lafuente Blanco, Maria Angeles Martinez-Grau, Concepcion Pedregal Tercero, Miguel Angel Toledo Escribano
  • Spiropiperidine compounds as ORL-1 receptor antagonists
    Patent number: 8232289
    Abstract: An ORL-1 receptor antagonist of the formula: its uses, and methods for its preparation are described.
    Type: Grant
    Filed: November 10, 2010
    Date of Patent: July 31, 2012
    Assignee: Eli Lilly and Company
    Inventors: Ana Belen Benito Collado, Nuria Diaz Buezo, Alma Maria Jimenez-Aguado, Celia Lafuente Blanco, Maria Angeles Martinez-Grau, Concepcion Pedregal-Tercero, Miguel Angel Toledo Escribano
  • SPIROPIPERIDINE COMPOUNDS AS ORL-1 RECEPTOR ANTAGONISTS
    Publication number: 20110118251
    Abstract: An ORL-1 receptor antagonist of the formula: its uses, and methods for its preparation are described.
    Type: Application
    Filed: November 10, 2010
    Publication date: May 19, 2011
    Applicant: ELI LILLY AND COMPANY
    Inventors: Ana Belen BENITO COLLADO, Nuria DIAZ BUEZO, Alma Maria JIMENEZ-AGUADO, Celia LAFUENTE BLANCO, Maria Angeles MARTINEZ-GRAU, Concepcion PEDREGAL-TERCERO, Miguel Angel TOLEDO ESCRIBANO